Overview of prospective phase 3 PlanB trial of 21-gene Recurrence Score® result in breast cancer - European Medical Journal

Overview of prospective phase 3 PlanB trial of 21-gene Recurrence Score® result in breast cancer

Oncology

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German Study Group, Mönchengladbach, Germany, explains the rationale and design of PlanB, a prospective phase 3 trial evaluating the Oncotype DX® 21-gene Recurrence Score® result for defining a low-risk subgroup of breast cancer patients with node-negative disease and high-risk clinicopathological factors as well as patients with node-positive disease who could be treated with adjuvant endocrine therapy alone.

This content is supported by Genomic Health, Inc.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now